 |
By 2030, the global demand for biologics is projected to grow at a CAGR of 8.7% and the challenges, risks, and costs of bringing large molecule products to market are growing exponentially. For new and emerging pharma companies who want to bring their new biologic to market, meeting clinical trial milestones to be first to market with their molecule can be difficult. Time is of the essence. To start, they need to accelerate their journey from lab to clinic by mitigating unnecessary risks as early as possible. In this executive summary, you will learn:
|
